Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future
Open Access
Abstract
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-stage renal cell carcinomas (RCC), but more recently, combination regimens with immune checkpoint inhibitors have demonstrated better outcomes. Despite this, the majority of affected patients still eventually experience progressive disease due to therapeutic resistance mechanisms, and there remains a need to develop novel therapeutic strategies. This article will review the synergistic mechanisms behind angiogenesis and immunomodulation in the tumor microenvironment and discuss the pre-clinical and clinical evidence for both clear-cell and non-clear-cell RCC, exploring opportunities for future growth in this exciting area of drug development.Keywords
This publication has 125 references indexed in Scilit:
- Reviews Spontaneous regression of renal cell carcinomaContemporary Oncology, 2013
- mTOR Inhibitors in Advanced Renal Cell CarcinomaHematology/Oncology Clinics of North America, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Trophic macrophages in development and diseaseNature Reviews Immunology, 2009
- Anti-angiogenesis: making the tumor vulnerable to the immune systemCancer Immunology, Immunotherapy, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995